Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the ri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Goss, P.E., Ingle, J.N., Pritchard, K.I., Robert, N.J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., Strasser-Weippl, K., Rubin, S., Sturtz, K., Wolff, A.C., Winer, E., Hudis, C., Stopeck, A., Beck, J.T., Kaur, J.S., Whelan, K., Tu, D., Parulekar, W.R.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024713/
https://ncbi.nlm.nih.gov/pubmed/27264120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1604700
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items